Clinical trials: Unresectable Cancer
Gastro-entero-pancreatic Carcinoma, Esophageal Neuroendocrine Carcinoma
Octreotide LAR as Maintenance Treatment for Patients With NEC
This is phase II study on the efficacy of octreotide lar as maintenance treatment after first-line chemotherapy for patients with unresectable or metastatic gastro-entero-pancreatic or esophageal neuroendocrine carcinomas.
- Trial name
- NCT02409849
- Testing
- Octreotide lar
- Where
- China
- Volunteers
- 92 people
- Sponsor
- Peking University
Cholangiocarcinoma
Chart Review: Unresectable/Metastatic Cholangiocarcinoma Treated With Irinotecan, Capecitabine and Celecoxib
Chart Review on Patients with unresectable/metastatic cholangiocarcinoma treated in the UNM Cancer Center with a combination of irinotecan, capecitabine and celecoxib.
- Trial name
- NCT00320918
- Where
- United States
- Volunteers
- 10 people
- Sponsor
- University of New Mexico
Brain Tumors, Central Nervous System Tumors
Electroacupuncture in Treating Delayed Nausea and Vomiting in Patients Receiving Chemotherapy For Newly Diagnosed Childhood Sarcoma, Neuroblastoma, Nasopharyngeal Cancer, Germ Cell Tumors, or Hodgkin Lymphoma
RATIONALE: Electroacupuncture may help to reduce or prevent delayed nausea and vomiting in patients treated with chemotherapy. PURPOSE: This randomized clinical trial is studying the effectiveness of electroacupuncture in…
- Conditions
- Brain Tumors, Central Nervous System Tumors, Childhood Germ Cell Tumor, Extragonadal Germ Cell Tumor
- Trial name
- NCT00040911
- Testing
- electroacupuncture therapy, quality-of-life assessment
- Where
- United States
- Volunteers
- 17 people
- Sponsor
- Children's Oncology Group
Liver Cancer
A Humanitarian Device Exemption Treatment Protocol of TheraSphere For Treatment of Unresectable Hepatocellular Carcinoma
To provide Therasphere treatment for patients diagnosed with unresectable liver cancer.
- Trial name
- NCT01076517
- Testing
- Therasphere
- Where
- United States
- Sponsor
- Stanford University
Progression-free Survival, Overall Survival
Apatinib Plus Anti-PD1 Therapy for Advanced Osteosarcoma
After standard multimodal therapy, the prognosis of relapsed and unresectable high-grade osteosarcoma is dismal and unchanged over the last decades.
- Conditions
- Progression-free Survival, Overall Survival, Clinical Benefit Rate, Toxicity
- Trial name
- APFAO (NCT03359018)
- Testing
- Apatinib, SHR-1210
- Where
- 2 sites in China
- Volunteers
- 43 people
- Sponsor
- Peking University People's Hospital
Advanced Lymphoma, Advanced Malignant Solid Neoplasm
Testing a New Anti-cancer Drug Combination, Entinostat and GSK525762C, for Advanced and Refractory Solid Tumors and Lymphomas
This phase I trial studies the side effects and best dose of GSK525762C (molibresib besylate) and entinostat in treating patients with solid tumors or lymphomas that have spread to other parts of the body (advanced) or are not…
- Conditions
- Advanced Lymphoma, Advanced Malignant Solid Neoplasm, Ann Arbor Stage III B-Cell Non-Hodgkin Lymphoma, Ann Arbor Stage III T-Cell Non-Hodgkin Lymphoma
- Trial name
- NCT03925428
- Testing
- Entinostat, Molibresib
- Sponsor
- National Cancer Institute (NCI)
Neuroblastoma
Monoclonal Antibody 3F8 and Sargramostim in Treating Patients With Neuroblastoma
RATIONALE: Monoclonal antibodies, such as monoclonal antibody 3F8, can locate tumor cells and either kill them or deliver tumor-killing substances to them without harming normal cells.
- Trial name
- NCT00072358
- Testing
- anti-GD2 murine IgG3 monoclonal antibody 3F8
- Where
- United States
- Volunteers
- 291 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Neuroendocrine Tumors, Carcinoid Tumors
A Phase II Study of Pertuzumab and Erlotinib for Metastatic or Unresectable Neuroendocrine Tumors
To determine objective response rates (RR) by RECIST guideline version 1.1 for all patients treated with this strategy consisting of initial therapy with pertuzumab as a single agent and then addition of erlotinib for those who…
- Conditions
- Neuroendocrine Tumors, Carcinoid Tumors, Adrenal Gland Tumors, Neuroblastoma
- Trial name
- NCT00947167
- Testing
- pertuzumab, erlotinib
- Where
- United States
- Volunteers
- 4 people
- Sponsor
- Pamela L. Kunz
Solid Tumor
A Study of OMX-0407 in Patients With Previously Treated Solid Tumours That Can't be Removed Surgically
The main purpose of the dose escalation phase of the study is to determine the safety of different doses of OMX-0407. The dose expansion (phase Ib) part of the study will evaluate efficacy, safety and tolerability at a dose…
- Trial name
- NCT05826600
- Testing
- OMX-0407
- Where
- 24 sites in Belgium, France and 1 more
- Volunteers
- 68 people
- Sponsor
- iOmx Therapeutics AG
Renal Cell Carcinoma, Kidney Cancer
A Study to Observe the Onset of Immune-related Adverse Reactions in Patients With Non-surgical or Renal Cell Carcinoma (RCC) That Has Spread
Patients with non-surgical or renal cell carcinoma that has spread who are starting treatment for the first time with Yervoy and Opdivo in the real world
- Trial name
- NCT03663946
- Testing
- Non-Interventional
- Where
- Japan
- Volunteers
- 81 people
- Sponsor
- Bristol-Myers Squibb
Soft Tissue Sarcoma (STS), Osteosarcoma
Cryoablation Plus Camrelizumab for Advanced Soft Tissue Sarcoma
The main purpose of this trial is to investigate and evaluate the efficacy of cryoablation combined with camrelizumab treatment to patients with advanced or inoperable soft tissue sarcomas after standard treatment failure.
- Trial name
- NCT07602049
- Testing
- Cryoablation therapy + anti-PD-1 antibody
- Where
- China
- Volunteers
- 57 people
- Sponsor
- Sun Yat-sen University
Carcinoma, Non-Small-Cell Lung
A Study of Participants in China With Non-Small-Cell Lung Cancer That is Unable to be Treated With Surgery
This is a multicenter, observational cohort study in China with both primary prospective data collection and retrospective collection of prior treatment information from medical records, which enrolls and follows patients who are…
- Trial name
- NCT05872763
- Where
- 12 sites in China
- Volunteers
- 901 people
- Sponsor
- Hoffmann-La Roche
Gastrointestinal Stromal Tumor
Comparison of Two Different Doses of STI571 in Treating Patients With Metastatic or Unresectable Gastrointestinal Stromal Tumor
Randomized phase III trial to compare the effectiveness of two different doses of STI571 in treating patients who have metastatic or unresectable gastrointestinal stromal tumor.
- Trial name
- NCT00009906
- Testing
- Imatinib Mesylate
- Where
- 144 sites in United States, Canada and 1 more
- Volunteers
- 748 people
- Sponsor
- National Cancer Institute (NCI)
Sarcoma
A Study Evaluating the Efficacy and Safety of Risvutatug Rezetecan in Participants With Advanced Sarcomas (EMBOLD Sarcoma-202)
The main goal of this study is to test a new medicine, Risvutatug Rezetecan also called Ris-Rez. We want to see if this medicine can help people with certain types of cancer, whether its safe to use, how well people tolerate it…
- Trial name
- NCT07602777
- Testing
- Ris-Rez, G-CSF
- Where
- 13 sites in United States, Canada and 4 more
- Volunteers
- 64 people
- Sponsor
- GlaxoSmithKline
Advanced Alveolar Soft Part Sarcoma, Advanced Soft Tissue Sarcoma
Testing Atezolizumab With Selinexor in People ≥ 12 Years Old With Alveolar Soft Part Sarcoma, AXIOM Trial
This phase II trial tests whether atezolizumab in combination with selinexor works to shrink tumors in patients with alveolar soft part sarcoma and whether the study drugs are better than the usual approach in treating this type…
- Conditions
- Advanced Alveolar Soft Part Sarcoma, Advanced Soft Tissue Sarcoma, Metastatic Alveolar Soft Part Sarcoma, Refractory Alveolar Soft Part Sarcoma
- Trial name
- NCT05333458
- Testing
- Atezolizumab, Biopsy Procedure, Biospecimen Collection
- Where
- 13 sites in United States
- Volunteers
- 27 people
- Sponsor
- National Cancer Institute (NCI)
Metastatic NUT Carcinoma, Unresectable NUT Carcinoma
Testing of the Addition of a New Anti-cancer Drug, Molibresib, to Chemotherapy Treatment (Etoposide and Cisplatin) for Patients With NUT Carcinoma
This phase I/II trial studies the side effects and best dose of molibresib when given together with chemotherapy (etoposide and cisplatin) and how well they work for the treatment of NUT cancer that has spread to other places in…
- Trial name
- NCT04116359
- Testing
- Cisplatin, Etoposide, Etoposide Phosphate
- Sponsor
- National Cancer Institute (NCI)
Soft Tissue Sarcoma
A Japanese Trial of TH-302 in Subjects With Locally Advanced Unresectable or Metastatic Soft Tissue Sarcoma
This is a Phase 2, single-arm, Japanese multicenter trial to evaluate the safety, tolerability, and efficacy of TH-302 in combination with doxorubicin in subjects with locally advanced unresectable or metastatic soft tissue…
- Trial name
- NCT02255110
- Testing
- TH-302, Doxorubicin
- Where
- 2 sites in Japan
- Volunteers
- 6 people
- Sponsor
- Merck KGaA, Darmstadt, Germany
Hepatocellular Carcinoma, Liver Cancer
Comparison of Criteria for Liver Transplantation in Hepatocellular Carcinoma
Hepatocellular cancer is the 6th most common seen disease in the world and the 3rd in cancer-related deaths. Liver transplantation is the primary curative treatment of HCC, as it eliminates liver cancer and underlying cirrhosis.
- Conditions
- Hepatocellular Carcinoma, Liver Cancer, Advanced Adult Hepatocellular Carcinoma, Cirrhosis, Liver
- Trial name
- NCT04576572
- Where
- Turkey (Türkiye)
- Volunteers
- 424 people
- Sponsor
- Inonu University
Non-Small Cell Lung Cancer, Medullary Thyroid Cancer
Pre-Approval Access Program (PAAP) for Pralsetinib (BLU-667) in Patients With Unresectable or Metastatic NSCLC or MTC
This is a global, multicenter, open-label pre-approval access program to provide access to pralsetinib (BLU-667) until such time that pralsetinib becomes available through other mechanisms or the Sponsor chooses to discontinue…
- Trial name
- NCT04204928
- Testing
- pralsetinib (BLU-667)
- Sponsor
- Blueprint Medicines Corporation
Malignant Melanoma
Study Of Zelboraf (Vemurafenib) in Patients With Locally-Advanced, Unresectable, Stage IIIc Or Metastatic Melanoma and Activating Exon 15 BRAF Mutations Other Than V600E
This is an open-label, multicenter, single-agent, phase II study of continuous oral Zelboraf (vemurafenib) in participants with locally-advanced, unresectable, stage IIIc or metastatic melanoma and activating exon 15 BRAF…
- Trial name
- NCT01586195
- Testing
- Vemurafenib
- Where
- 15 sites in United States
- Volunteers
- 31 people
- Sponsor
- Genentech, Inc.